Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.

Glatzer, Markus; Leskow, Pawel; Caparrotti, Francesca; Elicin, Olgun; Furrer, Markus; Gambazzi, Franco; Dutly, André; Gelpke, Hans; Guckenberger, Matthias; Heuberger, Jürg; Inderbitzi, Rolf; Cafarotti, Stefano; Karenovics, Wolfram; Kestenholz, Peter; Kocher, Gregor; Kraxner, Peter; Krueger, Thorsten; Martucci, Francesco; Oehler, Christoph; Ozsahin, Mahmut; ... (2021). Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. Translational lung cancer research, 10(4), pp. 1960-1968. AME Publishing 10.21037/tlcr-20-1210

tlcr-10-04-1960.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (667kB) | Preview


Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy (CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating a significant survival benefit for either of these approaches, the selection between treatments is not always straightforward and can come down to physician and patient preference. The very heterogeneous definition of resectability of N2 disease makes the decision-making process even more complex.


We evaluated the treatment strategies for preoperatively diagnosed stage III cN2 NSCLC among Swiss thoracic surgeons and radiation oncologists. Treatment strategies were converted into decision trees and analysed for consensus and discrepancies. We analysed factors relevant to decision-making within these recommendations.


For resectable "non-bulky" mediastinal lymph node involvement, there was a trend towards surgery. Numerous participants recommend a surgical approach outside existing guidelines as long as the disease was resectable, even in multilevel N2. With increasing extent of mediastinal nodal disease, multimodal treatment based on radiotherapy was more common.


Both, surgery- or radiotherapy-based treatment regimens are feasible options in the management of Stage III N2 NSCLC. The different opinions reflected in the results of this manuscript reinforce the importance of a multidisciplinary setting and the importance of shared decision-making with the patient.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery
04 Faculty of Medicine > Faculty Institutions > Teaching Staff, Faculty of Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Glatzer, Markus; Eliçin, Olgun; Kocher, Gregor; Zaugg, Kathrin and Putora, Paul Martin


600 Technology > 610 Medicine & health




AME Publishing




Beatrice Scheidegger

Date Deposited:

16 Jun 2021 15:00

Last Modified:

10 Jan 2022 07:44

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Non-small cell lung cancer (NSCLC) decision-making radiotherapy stage III N2 lung cancer surgery




Actions (login required)

Edit item Edit item
Provide Feedback